1-6 of 6
Michael E Williams, M.D.
Close
Sort by
Journal Articles

Fluoroquinolone Prophylaxis Following Induction Chemotherapy in Patients with Acute Leukemia: Patterns of Infection

Patrick Reagan, MD, Tri Le, MD, Michael E. Williams, M.D., Nolan Wages, PhD
Journal: Blood
Blood (2012) 120 (21): 2077.
https://doi.org/10.1182/blood.V120.21.2077.2077
Published: 2012
Journal Articles

Quality of Life Results From Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Indolent Non-Hodgkin's Lymphoma

Lynne I. Wagner, Ph.D., Fengmin Zhao, Ph.D., Michael E. Williams, M.D., Randy D. Gascoyne, MD, John C. Krauss, M.D., David Cella, Ph.D., Sandra J. Horning, M.D., Brad S. Kahl, M.D.
Journal: Blood
Blood (2012) 120 (21): 235.
https://doi.org/10.1182/blood.V120.21.235.235
Published: 2012
Journal Articles

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study

Andre Goy, MD, Rajni Sinha, MD, MRCP, Michael E. Williams, M.D., Sevgi Kalayoglu Besisik, Johannes Drach, Radhakrishnan Ramchandren, MD, Michael J. Robertson, MD, Irit Avivi, MD, Jacob M. Rowe, Raoul Herbrecht, MD, Achiel Van Hoof, Miklos Egyed, MD, PhD, Lei Zhang, MD, Sherri Cicero, Tommy Fu, Thomas E. Witzig, MD
Journal: Blood
Blood (2012) 120 (21): 905.
https://doi.org/10.1182/blood.V120.21.905.905
Published: 2012
Journal Articles

Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma

Brad S. Kahl, MD, Fangxin Hong, PhD, Michael E Williams, M.D., Randy D. Gascoyne, MD, Lynne I Wagner, PhD, John C. Krauss, MD, Sandra J. Horning, MD
Journal: Blood
Blood (2011) 118 (21): LBA-6.
https://doi.org/10.1182/blood.V118.21.LBA-6.LBA-6
Published: 2011
Journal Articles

Nuclear Expression of the Sox 11 Transcription Factor in Mantle Cell Lymphoma, and Cytoplasmic Expression in Follicular Lymphoma and Multiple Myeloma: Pathogenetic Implications.

Michael E Williams, M.D., Sarah Rutherford, M.D., Yunjia Tang, M.D., John Cousar, M.D.
Journal: Blood
Blood (2009) 114 (22): 2925.
https://doi.org/10.1182/blood.V114.22.2925.2925
Published: 2009
Journal Articles

A Pilot Study of Thrice-Weekly Low Dose Rituximab (RTX) in the Treatment of Chronic Lymphocytic Leukemia (CLL) Suggests Enhanced Therapeutic Targeting Compared to Standard Dose Regimens.

Ronald P. Taylor, Ph.D., Andrew W. Pawluczkowycz, M.S., Paul V. Beum, Ph.D., Adam D. Kennedy, M.S., Margaret A. Lindorfer, Ph.D., John J. Densmore, M.D., Ph.D., Jane Eggleton, R.N., Karen L. LoRusso, M.D., Michael E. Williams, M.D.
Journal: Blood
Blood (2004) 104 (11): 2520.
https://doi.org/10.1182/blood.V104.11.2520.2520
Published: 2004